iLite® anti-HER2 ADCC Activity Set

BM5090

iLite® ADCC anti-HER2 Assay Ready Cells allow you to measure the ADCC activity of your anti-HER2 antibody in a simple, rapid and sensitive manner.

Therapeutic antibodies are increasingly used to treat different types of cancer, including breast cancer. The activity of a number of therapeutic antibodies is mediated at least in part by antibody dependent cell-mediated cytotoxicity (ADCC), including trastuzumab, an anti-HER2 antibody commonly used for treating HER2 positive breast cancer patients.

This product contains a packaged set of the three individual products, one vial of each:

  • iLite® ADCC Effector (V) Assay Ready Cells (BM5001)
  • iLite® ADCC Target HER2 (+) Assay Ready Cells (BM5011)
  • iLite® ADCC Target HER2 (-) Assay Ready Cells (BM5016)

All three products are genetically engineered human cells to be used for measuring the ADCC activity of anti-HER2 antibodies.

FOR RESEARCH USE ONLY

€ 950

Add to cart    
iLite® anti-HER2 ADCC Activity Set

At a glance


Product code BM5090
Assay target ADCC
Assay target HER2
Size 3 vials
Read-out of results Quantitative,
Detection system Luminescence
Regulatory status Research Use Only

What's in the box?


3 vials of iLite® Assay Ready Cells (>250 µL). For contents of the individual vials, please consult the specific product specifications.

Documents

More content

Get access to scientific material, posters and more.

More downloads

Insights

Did you know?

Need help?

We can help! Just ask us a question.